Theratechnologies EV / EBITDA
Was ist das EV / EBITDA von Theratechnologies?
EV / EBITDA von Theratechnologies, Inc. ist N/A
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf TSX im Vergleich zu Theratechnologies
Was macht Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Unternehmen mit ev / ebitda ähnlich Theratechnologies
- Avira Resources hat EV / EBITDA von N/A
- Avalon GloboCare hat EV / EBITDA von N/A
- Westport Fuel Systems hat EV / EBITDA von N/A
- Sequana Medical NV hat EV / EBITDA von N/A
- Mint Payments hat EV / EBITDA von N/A
- FRX Innovations hat EV / EBITDA von N/A
- Theratechnologies hat EV / EBITDA von N/A
- Bubblr Inc hat EV / EBITDA von N/A
- Mithra Pharmaceuticals SA hat EV / EBITDA von N/A
- Auxly Cannabis hat EV / EBITDA von N/A
- Spey Resources Corp hat EV / EBITDA von N/A
- Golden Deeps hat EV / EBITDA von N/A
- Red Lion Hotels hat EV / EBITDA von N/A